1232685-21-0

Basic information

• Product Name: (4S)-N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-5-methyl-indazol-6-yl]-4-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide
• Synonyms: (4S)-N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-5-methyl-indazol-6-yl]-4-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide
• CAS NO: 1232685-21-0
• Molecular Weight: 522.695
• Mol File: 1232685-21-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (4S)-N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-5-methyl-indazol-6-yl]-4-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-5-methyl-indazol-6-yl]-4-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide(1232685-21-0)
• EPA Substance Registry System: (4S)-N-[1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-5-methyl-indazol-6-yl]-4-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide(1232685-21-0)

Safety Data

• Hazardous Substances Data: 1232685-21-0(Hazardous Substances Data)

Upstream product

• 1232685-12-9 tert-butyl-dimethyl-[2-(5-methyl-6-nitro-indazol-1-yl)ethoxy]silane 
• 72521-00-7 5-methyl-6-nitro-1H-indazole 
• 1220248-47-4 (S)-4-(4-fluorophenyl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylic acid methyl ester 
• 1224442-80-1 (R)-3-(4-fluorophenyl)-2-formylpentanedioic acid 1-methyl ester 
• 4926-12-9 4-(4-fluorophenyl)dihydropyran-2,6(3H)-dione 
• 2124-47-2 5-nitro-2,4-dimethylaniline 
• 1232506-24-9 (4S)-4-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-pyridine-5-carbonyl chloride 
• 1232685-13-0 1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-5-methyl-indazol-6-amine 

Downstream Products

• 1232684-78-4 (4S)-4-(4-fluorophenyl)-N-[1-(2-hydroxyethyl)-5-methyl-indazol-6-yl]-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide 

Relevant articles and documents

Novel Series of Dihydropyridinone P2X7 Receptor Antagonists

Identification of singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clinical candidates 17 and 19. During development, a number of issues were successfully addressed, such as metabolic stability, plasma stability, GSH adduct formation, and aniline mutagenicity. Thus, careful modification of the molecule, such as conversion of the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper substitution at C-5″, and in some cases addition of fluorine atoms to the aniline ring allowed for the identification of a novel class of potent P2X7 inhibitors suitable for evaluating the role of P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders.